Curcumin improves amyloid β-peptide (1-42) induced spatial memory deficits through BDNF-ERK signaling pathway

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Zhang, Lu ^a,b   Fang, Yu ^a,c   Xu, Yuming ^a,b   Lian, Yajun ^b   Xie, Nanchang ^b   Wu, Tianwen ^b   Zhang, Haifeng ^b   Sun, Limin ^c   Zhang, Ruifang ^c   Wang, Zhenhua ^c  

^a Open Laboratory of Key Discipline of Clinical Medical Sciences   (China)

^b ZHENGZHOU UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BRAIN DERIVED NEUROTROPHIC FACTOR; CURCUMIN; LENTIVIRUS VECTOR; MITOGEN ACTIVATED PROTEIN KINASE; SHORT HAIRPIN RNA; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); NEUROPROTECTIVE AGENT; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; ENZYME PHOSPHORYLATION; EXPLORATORY BEHAVIOR; GENE EXPRESSION; HIPPOCAMPUS; MALE; MEMORY DISORDER; MORRIS WATER MAZE TEST; NEUROPROTECTION; NONHUMAN; OPEN FIELD TEST; PROTEIN EXPRESSION; RAT; REFERENCE MEMORY; RODENT MODEL; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SPATIAL MEMORY; TREATMENT DURATION; UPREGULATION; WESTERN BLOTTING; Y-MAZE TEST; ANIMAL; CHEMICALLY INDUCED; COGNITION; DISEASE MODEL; DRUG EFFECTS; MAZE TEST; MEMORY DISORDERS; METABOLISM; PSYCHOLOGY; SHORT TERM MEMORY; SPRAGUE DAWLEY RAT;

CURCUMA LONGA; RATTUS; RODENTIA;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; COGNITION; CURCUMIN; DISEASE MODELS, ANIMAL; MALE; MAP KINASE SIGNALING SYSTEM; MAZE LEARNING; MEMORY DISORDERS; MEMORY, SHORT-TERM; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SPATIAL MEMORY;

EID: 84938634526     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0131525     Document Type: Article

References (50)

1. Acosta D, Wortmann M. Alzheimer's Disease International World Alzheimer Report 2009. Prince, M. 2009:1-92.
2. Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron. 1991; 6(4):487-98. Epub 1991/04/01. 0896-6273(91)90052-2 [pii]. PMID: 1673054.
3. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci. 1991; 12(10):383-8. Epub 1991/10/01. PMID: 1763432.
4. Qin XY, Cheng Y, Yu LC. Potential protection of curcumin against intracellular amyloid beta-induced toxicity in cultured rat prefrontal cortical neurons. Neuroscience letters. 2010; 480(1):21-4. doi: 10.1016/j.neulet.2010.05.062 PMID: 20638958.
5. Ye J, Zhang Y. Curcumin protects against intracellular amyloid toxicity in rat primary neurons. International journal of clinical and experimental medicine. 2012; 5(1):44-9. PMID: 22328947; PubMed Central PMCID: PMC3272685.
6. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2001; 21(21):8370-7. PMID: 11606625.
7. Begum AN, Jones MR, Lim GP, Morihara T, Kim P, Heath DD, et al. Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. The Journal of pharmacology and experimental therapeutics. 2008; 326(1):196-208. doi: 10.1124/jpet.108.137455 PMID: 18417733; PubMed Central PMCID: PMC2527621.
8. Sun CY, Qi SS, Zhou P, Cui HR, Chen SX, Dai KY, et al. Neurobiological and pharmacological validity of curcumin in ameliorating memory performance of senescence-accelerated mice. Pharmacology, biochemistry, and behavior. 2013; 105:76-82. doi: 10.1016/j.pbb.2013.02.002 PMID: 23402943.
9. Xu Y, Lin D, Li S, Li G, Shyamala SG, Barish PA, et al. Curcumin reverses impaired cognition and neuronal plasticity induced by chronic stress. Neuropharmacology. 2009; 57(4):463-71. doi: 10.1016/j.neuropharm.2009.06.010 PMID: 19540859.
10. Hoppe JB, Haag M, Whalley BJ, Salbego CG, Cimarosti H. Curcumin protects organotypic hippocampal slice cultures from Abeta1-42-induced synaptic toxicity. Toxicology in vitro: an international journal published in association with BIBRA. 2013; 27(8):2325-30. doi: 10.1016/j.tiv.2013.10.002 PMID: 24134851.
11. Hoppe JB, Coradini K, Frozza RL, Oliveira CM, Meneghetti AB, Bernardi A, et al. Free and nanoencapsulated curcumin suppress beta-amyloid-induced cognitive impairments in rats: involvement of BDNF and Akt/GSK-3beta signaling pathway. Neurobiology of learning and memory. 2013; 106:134-44. doi: 10.1016/j.nlm.2013.08.001 PMID: 23954730.
12. Barde YA, Davies AM, Johnson JE, Lindsay RM, Thoenen H. Brain derived neurotrophic factor. Progress in brain research. 1987; 71:185-9. PMID: 3588941.
13. Leibrock J, Lottspeich F, Hohn A, Hofer M, Hengerer B, Masiakowski P, et al. Molecular cloning and expression of brain-derived neurotrophic factor. Nature. 1989; 341(6238):149-52. doi: 10.1038/341149a0 PMID: 2779653.
14. Duman RS, Malberg J, Nakagawa S, D'Sa C. Neuronal plasticity and survival in mood disorders. Biological psychiatry. 2000; 48(8):732-9. PMID: 11063970.
15. Cotman CW, Berchtold NC. Exercise: a behavioral intervention to enhance brain health and plasticity. Trends in neurosciences. 2002; 25(6):295-301. PMID: 12086747.
16. Connor B, Dragunow M. The role of neuronal growth factors in neurodegenerative disorders of the human brain. Brain research Brain research reviews. 1998; 27(1):1-39. PMID: 9639663.
17. Murer MG, Yan Q, Raisman-Vozari R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Progress in neurobiology. 2001; 63(1):71-124. PMID: 11040419.
18. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 1976; 2(8000):1403. PMID: 63862.
19. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science. 1982; 215(4537):1237-9. PMID: 7058341.
20. Lu B, Nagappan G, Lu Y. BDNF and synaptic plasticity, cognitive function, and dysfunction. Handbook of experimental pharmacology. 2014; 220:223-50. doi: 10.1007/978-3-642-45106-5-9 PMID: 24668475.
21. Laske C, Stellos K, Hoffmann N, Stransky E, Straten G, Eschweiler GW, et al. Higher BDNF serum levels predict slower cognitive decline in Alzheimer's disease patients. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum. 2011; 14(3):399-404. doi: 10.1017/S1461145710001008 PMID: 20860877.
22. Typlt M, Mirkowski M, Azzopardi E, Ruettiger L, Ruth P, Schmid S. Mice with deficient BK channel function show impaired prepulse inhibition and spatial learning, but normal working and spatial reference memory. PloS one. 2013; 8(11):e81270. doi: 10.1371/journal.pone.0081270 PMID: 24303038; PubMed Central PMCID: PMC3841135.
23. Yamada K, Tanaka T, Mamiya T, Shiotani T, Kameyama T, Nabeshima T. Improvement by nefiracetam of beta-amyloid-(1-42)-induced learning and memory impairments in rats. British journal of pharmacology. 1999; 126(1):235-44. doi: 10.1038/sj.bjp.0702309 PMID: 10051141; PubMed Central PMCID: PMC1565810.
24. Yamada K, Tanaka T, Han D, Senzaki K, Kameyama T, Nabeshima T. Protective effects of idebenone and alpha-tocopherol on beta-amyloid-(1-42)-induced learning and memory deficits in rats: implication of oxidative stress in beta-amyloid-induced neurotoxicity in vivo. The European journal of neuroscience. 1999; 11(1):83-90. PMID: 9987013.
25. Nakamura S, Murayama N, Noshita T, Annoura H, Ohno T. Progressive brain dysfunction following intracerebroventricular infusion of beta(1-42)-amyloid peptide. Brain research. 2001; 912(2):128-36. PMID: 11532428.
26. Wang Y, Liu J, Zhang Z, Bi P, Qi Z, Zhang C. Anti-neuroinflammation effect of ginsenoside Rbl in a rat model of Alzheimer disease. Neuroscience letters. 2011; 487(1):70-2. doi: 10.1016/j.neulet.2010.09.076 PMID: 20933058.
27. Zhu X, Chen C, Ye D, Guan D, Ye L, Jin J, et al. Diammonium glycyrrhizinate upregulates PGC-1alpha and protects against Abeta1-42-induced neurotoxicity. PloS one. 2012; 7(4):e35823. doi: 10.1371/journal.pone.0035823 PMID: 22540007; PubMed Central PMCID: PMC3335163.
28. Narisawa-Saito M, Wakabayashi K, Tsuji S, Takahashi H, Nawa H. Regional specificity of alterations in NGF, BDNF and NT-3 levels in Alzheimer's disease. Neuroreport. 1996; 7(18):2925-8. PMID: 9116211.
29. Conner JM, Lauterborn JC, Yan Q, Gall CM, Varon S. Distribution of brain-derived neurotrophic factor (BDNF) protein and mRNA in the normal adult rat CNS: evidence for anterograde axonal transport. The Journal of neuroscience: the official journal of the Society for Neuroscience. 1997; 17(7):2295-313. PMID: 9065491.
30. Ferrer I, Marin C, Rey MJ, Ribalta T, Goutan E, Blanco R, et al. BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies. Journal of neuropathology and experimental neurology. 1999; 58(7):729-39. PMID: 10411343.
31. Hock C, Heese K, Hulette C, Rosenberg C, Otten U. Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Archives of neurology. 2000; 57(6):846-51. PMID: 10867782.
32. Lee J, Fukumoto H, Orne J, Klucken J, Raju S, Vanderburg CR, et al. Decreased levels of BDNF protein in Alzheimer temporal cortex are independent of BDNF polymorphisms. Experimental neurology. 2005; 194(1):91-6. doi: 10.1016/j.expneurol.2005.01.026 PMID: 15899246.
33. Peng S, Wuu J, Mufson EJ, Fahnestock M. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. Journal of neurochemistry. 2005; 93(6):1412-21. doi: 10.1111/j.1471-4159.2005.03135.x PMID: 15935057.
34. Laske C, Stransky E, Leyhe T, Eschweiler GW, Maetzler W, Wittorf A, et al. BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls. Journal of psychiatric research. 2007; 41(5):387-94. doi: 10.1016/j.jpsychires.2006.01.014 PMID: 16554070.
35. Fischer W, Sirevaag A, Wiegand SJ, Lindsay RM, Bjorklund A. Reversal of spatial memory impairments in aged rats by nerve growth factor and neurotrophins 3 and 4/5 but not by brain-derived neurotrophic factor. Proceedings of the National Academy of Sciences of the United States of America. 1994; 91(18):8607-11. PMID: 8078930; PubMed Central PMCID: PMC44655.
36. Pelleymounter MA, Cullen MJ, Baker MB, Gollub M, Wellman C. The effects of intrahippocampal BDNF and NGF on spatial learning in aged Long Evans rats. Molecular and chemical neuropathology / sponsored by the International Society for Neurochemistry and the World Federation of Neurology and research groups on neurochemistry and cerebrospinal fluid. 1996; 29(2-3):211-26. doi: 10.1007/BF02815003 PMID: 8971697.
37. Croll SD, Suri C, Compton DL, Simmons MV, Yancopoulos GD, Lindsay RM, et al. Brain-derived neurotrophic factor transgenic mice exhibit passive avoidance deficits, increased seizure severity and in vitro hyperexcitability in the hippocampus and entorhinal cortex. Neuroscience. 1999; 93(4):1491-506. PMID: 10501474; PubMed Central PMCID: PMC2504500.
38. Kang H, Schuman EM. Long-lasting neurotrophin-induced enhancement of synaptic transmission in the adult hippocampus. Science. 1995; 267(5204):1658-62. PMID: 7886457.
39. Sweatt JD. Mitogen-activated protein kinases in synaptic plasticity and memory. Current opinion in neurobiology. 2004; 14(3):311-7. doi: 10.1016/j.conb.2004.04.001 PMID: 15194111.
40. Webster B, Hansen L, Adame A, Crews L, Torrance M, Thal L, et al. Astroglial activation of extracellular-regulated kinase in early stages of Alzheimer disease. Journal of neuropathology and experimental neurology. 2006; 65(2):142-51. doi: 10.1097/01.jnen.0000199599.63204.6f PMID: 16462205.
41. Dineley KT, Westerman M, Bui D, Bell K, Ashe KH, Sweatt JD. Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2001; 21(12):4125-33. PMID: 11404397.
42. Amadoro G, Ciotti MT, Costanzi M, Cestari V, Calissano P, Canu N. NMDA receptor mediates tau-induced neurotoxicity by calpain and ERK/MAPK activation. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103(8):2892-7. doi: 10.1073/pnas.0511065103 PMID: 16477009; PubMed Central PMCID: PMC1413822.
43. Hyman BT, Elvhage TE, Reiter J. Extracellular signal regulated kinases. Localization of protein and mRNA in the human hippocampal formation in Alzheimer's disease. The American journal of pathology. 1994; 144(3):565-72. PMID: 8129042; PubMed Central PMCID: PMC1887090.
44. Zhang L, Xu T, Wang S, Yu L, Liu D, Zhan R, et al. Curcumin produces antidepressant effects via activating MAPK/ERK-dependent brain-derived neurotrophic factor expression in the amygdala of mice. Behavioural brain research. 2012; 235(1):67-72. doi: 10.1016/j.bbr.2012.07.019 PMID: 22820234.
45. Wang R, Li YH, Xu Y, Li YB, Wu HL, Guo H, et al. Curcumin produces neuroprotective effects via activating brain-derived neurotrophic factor/TrkB-dependent MAPK and PI-3K cascades in rodent cortical neurons. Progress in neuro-psychopharmacology & biological psychiatry. 2010; 34(1):147-53. doi: 10.1016/j.pnpbp.2009.10.016 PMID: 19879308.
46. Tong L, Balazs R, Thornton PL, Cotman CW. Beta-amyloid peptide at sublethal concentrations downregulates brain-derived neurotrophic factor functions in cultured cortical neurons. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2004; 24(30):6799-809. doi: 10.1523/JNEUROSCI.5463-03.2004 PMID: 15282285.
47. Xu X, Zhan M, Duan W, Prabhu V, Brenneman R, Wood W, et al. Gene expression atlas of the mouse central nervous system: impact and interactions of age, energy intake and gender. Genome biology. 2007; 8(11):R234. doi: 10.1186/gb-2007-8-11-r234 PMID: 17988385; PubMed Central PMCID: PMC2258177.
48. Llorens-Martin M, Jurado J, Hernandez F, Avila J. GSK-3beta, a pivotal kinase in Alzheimer disease. Frontiers in molecular neuroscience. 2014; 7:46. doi: 10.3389/fnmol.2014.00046 PMID: 24904272; PubMed Central PMCID: PMC4033045.
49. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995; 378(6559):785-9. doi: 10.1038/378785a0 PMID: 8524413.
50. DaRocha-Souto B, Coma M, Perez-Nievas BG, Scotton TC, Siao M, Sanchez-Ferrer P, et al. Activation of glycogen synthase kinase-3 beta mediates beta-amyloid induced neuritic damage in Alzheimer's disease. Neurobiology of disease. 2012; 45(1):425-37. doi: 10.1016/j.nbd.2011.09.002 PMID: 21945540; PubMed Central PMCID: PMC3694284.